NCT06466031 2026-04-17
TYR-GLIO
Copernicus Memorial Hospital
Phase NA Recruiting
Clinical Trials
14 trialsNCT07301268 2026-04-08
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Recruiting
NCT06319027 2026-04-03
GABLE
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT05789394 2026-04-02
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Mayo Clinic
Phase 1 Recruiting
NCT04732065 2026-03-17
PNOC023
University of California, San Francisco
Phase 1 Recruiting
NCT07461948 2026-03-10
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
Jonsson Comprehensive Cancer Center
Phase 3 Recruiting
NCT07076472 2026-02-23
Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma
Mayo Clinic
Phase EARLY_PHASE1 Recruiting
NCT04047264 2026-02-12
Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies
Mayo Clinic
Phase NA Recruiting
NCT05879250 2025-12-30
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 2 Recruiting
NCT06090903 2025-11-10
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
Jonsson Comprehensive Cancer Center
Phase NA Recruiting
NCT07091864 2025-11-10
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
Mayo Clinic
Phase NA Recruiting
NCT05386043 2025-09-15
ReGIT
Indiana University
Recruiting
NCT06815029 2025-06-26
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
Phase 1 Recruiting
NCT06160206 2024-11-19
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Academic and Community Cancer Research United
Phase 2 Recruiting